Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety

Indication
Myotonic Dystrophy Type 1 (DM1); DM1; Myotonic Dystrophy

Other upcoming events for DYN

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, a

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety — DYN Phase 3 Readout | BioSniper